These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 33051812)

  • 1. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
    Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
    Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
    Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
    BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).
    Packwood K; Martland G; Sommerlad M; Shaw E; Moutasim K; Thomas G; Bateman AC; Jones L; Haywood L; Evans DG; Birch JM; Alsalmi OA; Henderson A; Poplawski N; Eccles DM
    J Pathol Clin Res; 2019 Jul; 5(3):189-198. PubMed ID: 31041842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of germline TP53 mutations in HER2+ breast cancer patients.
    Rath MG; Masciari S; Gelman R; Miron A; Miron P; Foley K; Richardson AL; Krop IE; Verselis SJ; Dillon DA; Garber JE
    Breast Cancer Res Treat; 2013 May; 139(1):193-8. PubMed ID: 23580068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
    Petry V; Bonadio RC; Cagnacci AQC; Senna LAL; Campos RDNG; Cotti GC; Hoff PM; Fragoso MCBV; Estevez-Diz MDP
    Fam Cancer; 2020 Jan; 19(1):47-53. PubMed ID: 31748977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
    Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
    JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.
    Masciari S; Dillon DA; Rath M; Robson M; Weitzel JN; Balmana J; Gruber SB; Ford JM; Euhus D; Lebensohn A; Telli M; Pochebit SM; Lypas G; Garber JE
    Breast Cancer Res Treat; 2012 Jun; 133(3):1125-30. PubMed ID: 22392042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
    Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
    Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    da Silva PFF; Goveia RM; Teixeira TB; Gamba BF; de Lima AP; Rogatto SR; Silveira-Lacerda EP
    Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625568
    [No Abstract]   [Full Text] [Related]  

  • 12. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.
    Mouchawar J; Korch C; Byers T; Pitts TM; Li E; McCredie MR; Giles GG; Hopper JL; Southey MC
    Cancer Res; 2010 Jun; 70(12):4795-800. PubMed ID: 20501846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
    Fortuno C; James PA; Spurdle AB
    Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.
    Franceschi S; Spugnesi L; Aretini P; Lessi F; Scarpitta R; Galli A; Congregati C; Caligo MA; Mazzanti CM
    Carcinogenesis; 2017 Sep; 38(9):938-943. PubMed ID: 28911001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
    Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
    JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients.
    Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Kho PF; James PA; Spurdle AB
    Cancer Genet; 2019 Jun; 235-236():21-27. PubMed ID: 31296311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.
    Ginsburg OM; Akbari MR; Aziz Z; Young R; Lynch H; Ghadirian P; Robidoux A; Londono J; Vasquez G; Gomes M; Costa MM; Dimitrakakis C; Gutierrez G; Pilarski R; Royer R; Narod SA
    Fam Cancer; 2009; 8(4):563-7. PubMed ID: 19714488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathologic features of breast cancer in Li-Fraumeni syndrome.
    Kuba MG; Lester SC; Bowman T; Stokes SM; Taneja KL; Garber JE; Dillon DA
    Mod Pathol; 2021 Mar; 34(3):542-548. PubMed ID: 32636452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
    Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
    BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.